The (10⁶⁰) Paradox: Is Big Pharma’s AI Just Automating Risk Aversion?

Artificial intelligence promises to transform drug discovery, but is it really exploring new chemical frontiers or simply making us more efficient at navigating what we already know? Examining the MELLODDY consortium, one of pharma's largest federated machine learning initiatives, this article explores whether the industry's most celebrated AI successes are optimising historical knowledge rather than expanding the boundaries of innovation.